3 results
The Primary objective is to determine whether the administration of ACH 0144471 can increase C3 levels in patients with low C3 levels due to either C3G or IC-MPGN.The secondary objectives are:* To evaluate the safety and tolerability of ACH 0144471…
See protocol P5:The primary objective of this study is to evaluate the efficacy of 12 months of oral ACH-0144471 in participants with C3G or ICMPGNbased on histologic scoring and proteinuriaThe secondary objectives of this study are: * To evaluate…
The primary objective is to test the role of NMDA receptor-dependent learning in an experimental model of conditioned nocebo effects on self-reported pain (sub-study 1) and itch (sub-study 2). Secondary objectives are to examine the role of NMDA…